EuroPCR 2023: Late-Breaking Science Video Collection
Published: 18 May 2023
-
Views:
2136 -
Likes:
7
-
Views:
2136 -
Likes:
7
-
Up Next
-
3m 30sPart 1 | Session 4 TRILUMINATE Pivotal: TEER for Tricuspid Regurgitation
-
6m 7sPart 1 | Session 5 EBC MAIN Three-Year Follow Up
-
4m 59sPart 1 | Session 6 TVT Registry Analysis: TAVR in Patients with Cardiogenic Shock
-
2m 35sPart 1 | Session 7 FAME III Three-Year Follow-Up
-
29m 21sPart 2 | Session 1 View from the Thoraxcenter: EuroPCR 23 Late-breaking Science Preview
-
30m 41sPart 2 | Session 2 View from the Thoraxcenter: What's Hot at EuroPCR 23?
-
1m 5sPart 4 | Session 1 Dr Lim: Patient Care and Finding Your Passion
-
1m 51s
-
1m 45sPart 4 | Session 3 Dr Sorajja: Why He Chose Cardiovascular Medicine
-
5m 41sPart 1 | Session 1 EBC TWO Five Year Follow-Up: Two-Stent Vs One for Large Bifurcation Lesions Sandeep Arunothayaraj
-
6m 12sPart 1 | Session 2 BASILICA Vs Chimney-Stenting for TAVR-Related Coronary Obstruction Antonio Mangieri
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2023 from selected faculty in our Highlights Reviews.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of EuroPCR 2023.
More from this programme
Part 1
Expert Interviews
Short, concise overviews of the key data revealed at EuroPCR 2023, focussing on the results and impact on future research.
Part 2
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at EuroPCR 2023.
Part 3
Highlights Reviews
Commentary on the top late-breaking trials of EuroPCR 2023, as chosen by selected faculty.
Part 4
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
EuroPCR 23 - Dr Scott Lim (UVA Health Heart and Vascular Center, US) joins us to discuss the findings of the DRAGONFLY-DMR trial. (NCT04734756)
The purpose of the study was to assess the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system (Hangzhou Valgen Medtech) for treating symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation (DMR) in high surgical risk individuals.
Interview Questions:
- What is the background and rationale behind this study?
- What is the unique feature or design of the study device compared to other transcatheter edge-to-edge repair devices?
- How was the study designed, and what were the baseline characteristics of the patients included in the study?
- What are the key findings presented at EuroPCR, and what conclusions can be drawn from the them?
- What are the next steps?
Record on-site at EuroPCR 2023, Paris.
Editors: Jordan Rance and Mirjam Boros
Comments